SOURCE: Plandai Biotechnology, Inc.

Plandaí Biotechnology, Inc. Provides Shareholder Update on Completion of the Company’s Production Facility and Start of Commercial Production

The Update Also Provides New Information on Studies Involving Plandaí Products, Including an Upcoming Phase II Human Clinical Trial

Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today provided an update to shareholders that covers topics including the completion and optimization of the company’s state-of-the-art production facility in South Africa and the schedule for commencement of commercial production at the facility.

 

According to company spokesperson Louise Willemse, contractors are expected to finish all installation work at the company’s production facility on the Senteeko Tea Estate in South Africa between August 8 and Aug 15, 2014. The installation work includes all electrical, steam lines, equipment installation, and boiler system.

 

Engineers from the Indian contractor are scheduled to arrive on-site during the week of August 17 to complete the optimization and to initiate start-up of the facility. This process is anticipated to be complete during the first half of September 2014.

 

Commercial production of the Phytofare™ Catechin extract is then expected to commence with the first green tea crop of the season, which is entirely weather dependent but is anticipated to begin sometime in late September 2014 and continue through May of 2015. During the next winter season in South Africa, June through August 2015, the Company will begin processing Eureka lemons to produce approximately 200 kg of Phytofare™ Limonoid Glycoside Complex per day.

 

In addition to releasing the factory update, Plandaí also announced that the first two legs of the human clinical trial on the oral bioavailability of the company’s Phytofare™ Catechin Complex have been completed and results are expected to be released during the week of August 17, 2014. The third and final leg of the study will take place using Phytofare extract produced at the Senteeko facility and then entrapped in Pheroid® by scientists at North-West University in Potchefstroom, South Africa.

 

Concurrent with the third leg of the bioavailability study, Plandaí expects to commence a study testing the effects of Phytofare™ Catechin Complex in inducing weight loss.  The study is being designed as a Phase II human clinical trial and will involve 100 patients over 90 days in a double-blind protocol.

 

About Plandaí Biotechnology, Inc.

 

Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company’s products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.  For more information, please visit http://www.plandaibiotech.com.

 

Safe Harbor Statement

 

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

 

Contact: 

Andrew Beyer

Phone: 888-627-6902

Email:  investor@Plandaíbiotech.com

 

 

 

Source: Plandaí Biotechnology, Inc.